# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Cantor Fitzgerald analyst Ross Osborn maintains Cerus (NASDAQ:CERS) with a Overweight and raises the price target from $3 to...
Craig-Hallum initiates coverage on Cerus (NASDAQ:CERS) with a Buy rating and announces Price Target of $5.
U.S. stock futures were mixed this morning, with the Dow futures falling by around 10 points on Monday.
Cerus Corporation (NASDAQ:CERS) today announced that the U.S. Food and Drug Administration (FDA) has granted approval of 12-mon...
On Wednesday, Cathie Wood-led Ark Invest made a significant move by offloading shares of Block Inc (NYSE:SQ) amidst Bitcoin (CR...
Cerus reports results from the ReCePI Phase 3 trial for INTERCEPT Red Blood Cells, meeting the primary efficacy endpoint in car...